ArticleClinical rheumatology2026
Real-world retention of nintedanib and factors associated with treatment discontinuation in connective tissue disease-associated interstitial lung disease: a retrospective cohort study of 92 patients.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesTreatment discontinuation of nintedanib is an important clinical issue in patients with connective tissue disease-associated interstitial lung disease (CTD-ILD). This study aimed to evaluate real-world retention of nintedanib across CTD subtypes and to explore factors associated with treatment discontinuation.
methodsWe conducted a single-center retrospective study of consecutive patients with CTD-ILD who initiated nintedanib between June 2019 and December 2024. Clinical data, including baseline characteristics, concomitant therapies, and treatment outcomes, were collected. The primary outcome was the 48-week retention rate. Kaplan-Meier analysis and Cox proportional hazards models were used to evaluate factors associated with treatment discontinuation.
resultsA total of 92 patients were included (rheumatoid arthritis [RA], n = 25; idiopathic inflammatory myopathy [IIM], n = 25; systemic sclerosis [SSc], n = 21; microscopic polyangiitis [MPA], n = 10; Sjögren disease [SjD], n = 9). The 48-week retention rate was 82.6%, with a median treatment duration of 978 days (IQR, 586-1356). Retention was lowest in RA, with higher rates observed in other CTD subtypes. Stratified analyses showed that this difference was evident in patients aged < 65 years (p = 0.001) and those receiving an initial dose of 300 mg/day (p = 0.003), but not in older patients or those receiving < 300 mg/day. In univariable analysis, RA (HR 3.10, p = 0.024) and an initial dose of 300 mg/day (HR 2.67, p = 0.050) were associated with discontinuation. However, RA was not independently associated with discontinuation after adjustment for age and initial dose in the exploratory multivariable analysis.
conclusionsNintedanib showed favorable retention in CTD-ILD. Although retention appeared lower in RA, this difference may be influenced by patient characteristics such as age and initial dosing. Individualized dose selection and appropriate management of adverse events may improve treatment persistence. Key Points • Nintedanib showed favorable 48-week retention in patients with CTD-ILD in a real-world setting. • Lower retention observed in RA was influenced by age and initial dosing, rather than disease subtype alone.
Indexed as
Identifiers
42402543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.